UNLABELLED: Sorafenib--a broad kinase inhibitor--is a standard therapy for advanced hepatocellular carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC. However, the effects of sorafenib on tumor desmoplasia--and its consequences on treatment resistance--remain unknown. We demonstrate that sorafenib has differential effects on tumor fibrosis versus liver fibrosis in orthotopic models of HCC in mice. Sorafenib intensifies tumor hypoxia, which increases stromal-derived factor 1 alpha (SDF-1α) expression in cancer and stromal cells and, subsequently, myeloid differentiation antigen-positive (Gr-1(+)) myeloid cell infiltration. The SDF-1α/C-X-C receptor type 4 (CXCR4) pathway directly promotes hepatic stellate cell (HSC) differentiation and activation through the mitogen-activated protein kinase pathway. This is consistent with the association between SDF-1α expression with fibrotic septa in cirrhotic liver tissues as well as with desmoplastic regions of human HCC samples. We demonstrate that after treatment with sorafenib, SDF-1α increased the survival of HSCs and their alpha-smooth muscle actin and collagen I expression, thus increasing tumor fibrosis. Finally, we show that Gr-1(+) myeloid cells mediate HSC differentiation and activation in a paracrine manner. CXCR4 inhibition, using AMD3100 in combination with sorafenib treatment, prevents the increase in tumor fibrosis--despite persistently elevated hypoxia--in part by reducing Gr-1(+) myeloid cell infiltration and inhibits HCC growth. Similarly, antibody blockade of Gr-1 reduces tumor fibrosis and inhibits HCC growth when combined with sorafenib treatment. CONCLUSION: Blocking SDF-1α/CXCR4 or Gr-1(+) myeloid cell infiltration may reduce hypoxia-mediated HCC desmoplasia and increase the efficacy of sorafenib treatment.
UNLABELLED: Sorafenib--a broad kinase inhibitor--is a standard therapy for advanced hepatocellular carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC. However, the effects of sorafenib on tumor desmoplasia--and its consequences on treatment resistance--remain unknown. We demonstrate that sorafenib has differential effects on tumor fibrosis versus liver fibrosis in orthotopic models of HCC in mice. Sorafenib intensifies tumor hypoxia, which increases stromal-derived factor 1 alpha (SDF-1α) expression in cancer and stromal cells and, subsequently, myeloid differentiation antigen-positive (Gr-1(+)) myeloid cell infiltration. The SDF-1α/C-X-C receptor type 4 (CXCR4) pathway directly promotes hepatic stellate cell (HSC) differentiation and activation through the mitogen-activated protein kinase pathway. This is consistent with the association between SDF-1α expression with fibrotic septa in cirrhotic liver tissues as well as with desmoplastic regions of human HCC samples. We demonstrate that after treatment with sorafenib, SDF-1α increased the survival of HSCs and their alpha-smooth muscle actin and collagen I expression, thus increasing tumor fibrosis. Finally, we show that Gr-1(+) myeloid cells mediate HSC differentiation and activation in a paracrine manner. CXCR4 inhibition, using AMD3100 in combination with sorafenib treatment, prevents the increase in tumor fibrosis--despite persistently elevated hypoxia--in part by reducing Gr-1(+) myeloid cell infiltration and inhibits HCC growth. Similarly, antibody blockade of Gr-1 reduces tumor fibrosis and inhibits HCC growth when combined with sorafenib treatment. CONCLUSION: Blocking SDF-1α/CXCR4 or Gr-1(+) myeloid cell infiltration may reduce hypoxia-mediated HCC desmoplasia and increase the efficacy of sorafenib treatment.
Authors: Chee-Kin Hui; Nancy Leung; Tony W H Shek; Hung Yao; Wai-Ki Lee; Jak-Yiu Lai; Sik-To Lai; Wai-Man Wong; Lawrence S W Lai; Ronnie T P Poon; Chung-Mau Lo; Sheung-Tat Fan; George K K Lau Journal: Hepatology Date: 2007-09 Impact factor: 17.425
Authors: Yuqing Liu; Eric Lik Hang Lui; Scott L Friedman; Lei Li; Tao Ye; Yongjun Chen; Ronnie T Poon; Jana Wo; Tsz Wai Kok; Sheung Tat Fan Journal: Lab Invest Date: 2008-12-29 Impact factor: 5.662
Authors: Nuh N Rahbari; Dmitriy Kedrin; Joao Incio; Hao Liu; William W Ho; Hadi T Nia; Christina M Edrich; Keehoon Jung; Julien Daubriac; Ivy Chen; Takahiro Heishi; John D Martin; Yuhui Huang; Nir Maimon; Christoph Reissfelder; Jurgen Weitz; Yves Boucher; Jeffrey W Clark; Alan J Grodzinsky; Dan G Duda; Rakesh K Jain; Dai Fukumura Journal: Sci Transl Med Date: 2016-10-12 Impact factor: 17.956
Authors: Kohei Shigeta; Meenal Datta; Tai Hato; Shuji Kitahara; Ivy X Chen; Aya Matsui; Hiroto Kikuchi; Emilie Mamessier; Shuichi Aoki; Rakesh R Ramjiawan; Hiroki Ochiai; Nabeel Bardeesy; Peigen Huang; Mark Cobbold; Andrew X Zhu; Rakesh K Jain; Dan G Duda Journal: Hepatology Date: 2019-10-14 Impact factor: 17.425
Authors: John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain Journal: Cold Spring Harb Perspect Med Date: 2016-12-01 Impact factor: 6.915
Authors: Yeonjung Ha; Mohamed A Mohamed Ali; Molly M Petersen; William S Harmsen; Terry M Therneau; Han Chu Lee; Baek-Yeol Ryoo; Sally Bampoh; Kenneth A Valles; Mohamad Mady; Venkata R Missula; Kritika Prasai; Lewis R Roberts; Kang Mo Kim Journal: Hepatol Int Date: 2020-08-01 Impact factor: 6.047